Moderna Exceeds Expectations with Strong COVID Vaccine Sales

Moderna reported fourth-quarter revenue surpassing Wall Street expectations, driven by robust sales of its COVID-19 vaccine. The company, which faced financial challenges as demand for COVID vaccines declined post-pandemic, has been actively developing new products to address the revenue gap and demonstrate the sustainability of its mRNA technology.

In the fourth quarter, Moderna achieved revenue of $678 million, exceeding analyst estimates of $626.1 million. The company’s sales for 2025 reached $1.94 billion, higher than the average forecast of $1.89 billion, according to data compiled by LSEG. CEO Stéphane Bancel expressed optimism about the company’s prospects, stating, “We entered the new year with strong momentum despite the continued challenging environment in the U.S.”

Future Growth Plans Amid Regulatory Challenges

Moderna anticipates approximately 50 percent of its revenue will stem from the U.S., with the remainder coming from international markets. The company reiterated its forecast of 10 percent revenue growth by 2026 compared to the previous year, largely supported by the expansion of its next-generation COVID vaccine and strategic partnerships abroad.

Despite this positive outlook, the company faces setbacks, including the recent refusal by the U.S. Food and Drug Administration (FDA) to review its flu vaccine application due to alleged trial flaws. According to Vinay Prasad, the FDA’s top vaccine official, Moderna should have compared its flu vaccine to the standard high-dose flu shot for older adults. This recommendation raised questions about the trial’s design, which had previously received FDA approval when initiated 18 months ago.

Internal staff reviewers at the FDA had supported advancing the review, but Prasad overruled their decision, as reported by Stat. Moderna has criticized this move, asserting that the trial design was adequate and compliant with regulatory standards. The company has pinned hopes on its flu vaccine and a forthcoming COVID-flu combination shot to drive future revenue growth.

Financial Overview and Market Position

Despite the challenges, Moderna’s financial performance indicates resilience. The company reported a quarterly loss of $2.11 per share, an improvement from the $2.91 per share loss recorded a year earlier. As the company navigates a shifting market landscape, its commitment to innovation and strategic planning remains crucial for restoring profitability.

As Moderna continues to adapt to the changing demand for COVID-19 vaccines, its efforts in developing new products and enhancing its market position will be closely monitored by investors and industry analysts alike. The upcoming years are expected to reveal whether Moderna can successfully pivot and sustain its growth trajectory in a post-pandemic world.